Valneva SE (VALN) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Valneva SE (VALN) Healthcare & Pipeline Overview

Valneva SE is a specialty vaccine company focusing on prophylactic vaccines for infectious diseases, distinguishing itself through commercial travel vaccines like IXIARO and DUKORAL, and a pipeline including Lyme disease and chikungunya vaccine candidates, positioning it uniquely within the biotechnology sector.

What Is the Investment Thesis for VALN?

Valneva SE presents a compelling investment thesis based on its diverse vaccine portfolio and strategic partnerships. The company's commercial travel vaccines, including IXIARO and DUKORAL, provide a stable revenue base, while its pipeline of vaccine candidates, such as VLA15 (Lyme disease) and VLA1553 (chikungunya), offer significant growth potential. The collaboration with Pfizer for the Lyme disease vaccine is a key value driver, potentially generating substantial revenue upon successful commercialization. The company's gross margin of 38.7% indicates a solid foundation for profitability as pipeline products reach the market. However, the company's negative profit margin of -66.0% highlights the risks associated with ongoing R&D expenses and the uncertainty of clinical trial outcomes. Successful completion of Phase III trials for VLA1553 and subsequent regulatory approvals are critical catalysts for future growth.

Based on FMP financials and quantitative analysis

VALN Key Highlights

Market Cap of $647M reflects the company's current valuation in the biotechnology sector.

• Gross Margin of 38.7% indicates the profitability of Valneva's existing commercial vaccines.
• Profit Margin of -66.0% highlights the significant R&D investments and clinical trial expenses.
• Beta of 1.53 suggests higher volatility compared to the overall market, typical for biotechnology companies.
• Collaboration with Pfizer for Lyme disease vaccine development provides significant potential revenue streams.

Who Are VALN's Competitors?

VALN is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are VALN's Key Strengths?

Specialized vaccine portfolio targeting unmet needs.

• Strategic partnerships with Pfizer and Instituto Butantan.
• Established commercial infrastructure for travel vaccines.
• Advanced vaccine development capabilities.

What Are VALN's Weaknesses?

Negative profit margin due to high R&D expenses.

• Reliance on successful clinical trial outcomes.
• Limited financial resources compared to larger pharmaceutical companies.
• Concentration on specific vaccine markets.

What Could Drive VALN Stock Higher?

Phase III clinical trial results for VLA1553 (chikungunya vaccine) expected in late 2026.

• Commercialization and sales growth of IXIARO and DUKORAL travel vaccines.
• Potential regulatory approvals for VLA15 (Lyme disease vaccine) in 2027, pending successful Phase III trials.
• Expansion of strategic partnerships for vaccine development and distribution.

What Are the Key Risks for VALN?

Financial-distress signal — its Altman Z-Score of -1.82 sits in the distress zone (elevated bankruptcy risk).

• Inconsistent delivery — missed Wall Street EPS estimates in 5 of the last 8 reported quarters.
• Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures or regulatory setbacks for vaccine candidates.
• Competition from larger pharmaceutical companies with greater resources.
• Fluctuations in currency exchange rates affecting ADR value.
• Dependence on successful commercialization of pipeline products for future revenue growth.

What Are the Growth Opportunities for VALN?

• The Lyme disease vaccine candidate, VLA15, being co-developed with Pfizer, represents a significant growth opportunity. The market for Lyme disease vaccines is substantial, with an estimated 476,000 cases occurring annually in the United States. Successful Phase III trials and subsequent commercialization could generate substantial revenue for Valneva, leveraging Pfizer's global distribution network. The timeline for potential market entry is estimated within the next 2-3 years pending regulatory approvals.
• Valneva's chikungunya vaccine candidate, VLA1553, is another key growth driver. Chikungunya is a mosquito-borne viral disease with a significant global presence, particularly in tropical and subtropical regions. With Phase III clinical trials underway, successful completion and regulatory approval could lead to a first-in-class vaccine, addressing a critical unmet need. The market potential is estimated at several hundred million dollars annually, with potential launch within the next 1-2 years.
• Expansion of the commercial travel vaccine portfolio, including IXIARO and DUKORAL, provides a stable revenue base and opportunities for growth. As international travel rebounds, demand for these vaccines is expected to increase. Valneva can further expand its market reach through strategic partnerships and targeted marketing efforts, particularly in regions with high travel volumes and specific disease risks. This represents an ongoing growth opportunity with incremental revenue gains expected year-over-year.
• Strategic partnerships with organizations like Instituto Butantan for the chikungunya vaccine development, manufacturing, and marketing offer significant growth opportunities. These collaborations leverage the expertise and resources of partners to accelerate vaccine development and expand market access. By forging additional partnerships with research institutions and pharmaceutical companies, Valneva can diversify its pipeline and mitigate risks associated with individual vaccine candidates. This is an ongoing strategy with potential for long-term growth.
• Geographic expansion into new markets, particularly in Asia and Latin America, represents a substantial growth opportunity. These regions have a high prevalence of infectious diseases and a growing demand for preventative healthcare solutions. By establishing a presence in these markets through partnerships or direct sales, Valneva can tap into new revenue streams and diversify its geographic risk. This expansion strategy is expected to unfold over the next 3-5 years, requiring careful market analysis and strategic investments.

What Threats Does VALN Face?

• Clinical trial failures and regulatory setbacks.
• Competition from larger pharmaceutical companies.
• Changes in government regulations and healthcare policies.
• Economic downturns affecting travel and healthcare spending.

What Are VALN's Competitive Advantages?

• Specialty vaccine portfolio targeting unmet needs in infectious diseases.
• Strategic partnerships with major pharmaceutical companies like Pfizer.
• Proprietary vaccine technologies and manufacturing processes.
• Established commercial infrastructure for travel vaccines.

What Does VALN Do?

Founded in 1998 and headquartered in Saint-Herblain, France, Valneva SE is a specialty vaccine company dedicated to developing and commercializing prophylactic vaccines that address unmet needs in infectious diseases. The company's portfolio includes commercial vaccines for travelers, such as IXIARO, an inactivated Japanese encephalitis vaccine; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholerae and/or heat-labile toxin producing Enterotoxigenic Escherichia coli; and VLA2001, a vaccine candidate against SARS-CoV-2. Valneva is also developing VLA15, a vaccine candidate against Lyme disease that has completed Phase II clinical trials, and VLA1553, a vaccine candidate against the chikungunya virus, currently in Phase III clinical trials. These vaccine candidates highlight Valneva's commitment to addressing significant public health challenges. The company sells its products across the United States, Canada, Germany, Austria, the Nordics, the United Kingdom, other European countries, and internationally. Valneva has strategic collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine, and with Instituto Butantan for the development, manufacturing, and marketing of a single-shot chikungunya vaccine. These partnerships are crucial for expanding the reach and impact of Valneva's vaccine portfolio, leveraging the expertise and resources of established industry players. Valneva's focus on specialty vaccines and strategic collaborations positions it as a key player in the biotechnology industry, addressing critical needs in infectious disease prevention.

What Products and Services Does VALN Offer?

• Develop and commercialize prophylactic vaccines for infectious diseases.
• Offer commercial vaccines for travelers, including IXIARO (Japanese encephalitis) and DUKORAL (cholera/ETEC diarrhea).
• Develop vaccine candidates against Lyme disease (VLA15) and chikungunya virus (VLA1553).
• Collaborate with Pfizer on the development and commercialization of a Lyme disease vaccine.
• Partner with Instituto Butantan for the development, manufacturing, and marketing of a single-shot chikungunya vaccine.
• Sell vaccines and related products in the United States, Canada, Europe, and internationally.

How Does VALN Make Money?

• Develop and manufacture vaccines for infectious diseases.
• Commercialize vaccines through direct sales and distribution networks.
• Generate revenue through product sales and licensing agreements.
• Collaborate with partners for research, development, and commercialization of vaccines.

What Industry Does VALN Operate In?

Valneva operates within the biotechnology industry, which is characterized by high growth potential and significant R&D investment. The global vaccine market is projected to reach $62.4 billion by 2027, driven by increasing awareness of preventative healthcare and the emergence of new infectious diseases. Valneva's focus on specialty vaccines for travelers and its pipeline of vaccine candidates for diseases like Lyme and chikungunya position it to capitalize on these trends. The competitive landscape includes major pharmaceutical companies and specialized vaccine developers, requiring Valneva to differentiate itself through innovation and strategic partnerships.

Who Are VALN's Key Customers?

• Travelers seeking protection against infectious diseases.
• Healthcare providers administering vaccines to patients.
• Government agencies and public health organizations.
• Pharmaceutical companies partnering on vaccine development and distribution.

Wall Street analysts project Valneva SE revenue of about $154.6M for fiscal 2026, with EPS near $-0.79. The estimate reflects 5 contributing analysts.

Quarterly Financial Performance: Valneva SE

Revenue for Valneva SE came in at $35.5M during Q2 2026, a 14.9% improvement versus the preceding quarter. The company recorded a net loss of $31.7M, with diluted EPS of $-0.34. Quarter-over-quarter revenue has been mixed, typical for a small-cap company operating in Healthcare. Across the four most recent quarters, VALN averaged $-0.45 in diluted EPS.

VALN Valuation & Market Position

With a $647M market cap, Valneva SE sits in the small-cap segment of the market. Relative to its peer group, VALN's quantitative score of 44/100 is below the peer average of 78/100.

Key Financial Metrics

Return on assets is -40.6%, showing how much profit it generates from its asset base. Its free cash flow yield is -15.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.16 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -28.4%, the inverse of the P/E and a quick read on earnings relative to price.

Valneva SE's Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -1.82 places it in the distress zone, a signal of elevated financial risk.

Valneva SE has missed Wall Street's EPS estimate in 5 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 67.0% below estimates on average.

Company Profile

Valneva SE operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Saint-Herblain, FR. The company is led by CEO Thomas Lingelbach. VALN has traded publicly since 2021.

VALN Financials

VALN Latest News

VALN Analyst Consensus

VALN MoonshotScore

Latest Valneva SE Analysis

Valneva SE Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources